$77.95
-0.38%Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. It offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative, deformity, tumors, and trauma conditions; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional pain management solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. The company also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, it distributes human cell, tissue, and cellular and tissue-based products. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.
Last Annual Value
753.45M
3-Year CAGR
62%
5-Year CAGR
31%
10-Year CAGR
20%
| Company | Net Cash Provided by Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
![]() Globus Medical, Inc. NYSE:GMED | 753.45M | 45.7% | 22.2% | 15.9% | |
![]() Align Technology, Inc. NASDAQ:ALGN | 593.22M | -8.9% | -12.7% | 9.1% | |
![]() Molina Healthcare, Inc. NYSE:MOH | -535.00M | N/A | N/A | N/A | |
![]() AptarGroup, Inc. NYSE:ATR | 570.00M | -0.3% | 9.4% | 5.8% | |
![]() Penumbra, Inc. NYSE:PEN | 238.66M | 34.8% | 90.5% | N/A | |
![]() Henry Schein, Inc. NASDAQ:HSIC | 712.00M | 12.5% | 0.1% | 1.5% | |
![]() HealthEquity, Inc. NASDAQ:HQY | 457.09M | 44.8% | 20.3% | 32.9% | |
![]() DaVita Inc. NYSE:DVA | 1.89B | -2.9% | -0.5% | -0.4% | |
![]() Bio-Rad Laboratories, Inc. NYSE:BIO | 532.20M | 12.4% | -4.5% | 9.4% |
Continue your GMED research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.